Genmab A/S
(WBO:GMAB)
€
245
-1.8 (-0.73%)
Market Cap: 15.71 Bil
Enterprise Value: 11.88 Bil
PE Ratio: 22.03
PB Ratio: 3.66
GF Score: 90/100 - Q1 2024 Genmab A/S Earnings Call TranscriptMay 02, 2024€259.4 (-1.33%)Earnings
- Genmab A/S Annual Shareholders Meeting TranscriptMar 13, 2024
- Q4 2023 Genmab A/S Earnings Call TranscriptFeb 14, 2024€257.2 (+3.54%)Earnings
- Genmab A/S at JPMorgan Healthcare Conference TranscriptJan 10, 2024
- Genmab A/S R&D Update and ASH Data Review TranscriptDec 12, 2023
- Q3 2023 Genmab A/S Earnings Call TranscriptNov 07, 2023€276.1 (+3.02%)Earnings
- Genmab A/S at Morgan Stanley Global Healthcare Conference TranscriptSep 12, 2023
- Half Year 2023 Genmab A/S Earnings Call TranscriptAug 03, 2023€353.9 (-1.72%)Earnings
- Genmab A/S at Goldman Sachs Healthcare Conference TranscriptJun 13, 2023
- Q1 2023 Genmab A/S Earnings Call TranscriptMay 10, 2023€361.7 (-0.17%)Earnings
- Genmab A/S Annual Shareholders Meeting TranscriptMar 29, 2023
- Q4 2022 Genmab A/S Earnings Call TranscriptFeb 22, 2023€371.1Earnings
- Genmab A/S at JPMorgan Healthcare Conference TranscriptJan 11, 2023
- Genmab A/S R&D Update and ASH Data Review TranscriptDec 13, 2022
- Q3 2022 Genmab A/S Earnings Call TranscriptNov 09, 2022€396Earnings
- Genmab A/S at Morgan Stanley Global Healthcare Conference TranscriptSep 13, 2022
- Q2 2022 Genmab A/S Earnings Call TranscriptAug 10, 2022€346.1 (+0.32%)Earnings
- Genmab A/S at Goldman Sachs Global Healthcare Conference TranscriptJun 15, 2022
- Q1 2022 Genmab A/S Earnings Call TranscriptMay 11, 2022€275.2 (-1.50%)Earnings
- Genmab A/S Annual Shareholders Meeting TranscriptMar 29, 2022
- Q4 2021 Genmab A/S Earnings Call TranscriptFeb 16, 2022€299.1 (+0.17%)Earnings
- Genmab A/S at JPMorgan Healthcare Conference (Virtual) TranscriptJan 12, 2022
- Genmab A/S Virtual R&D Update and ASH Data Review TranscriptDec 14, 2021
- Q3 2021 Genmab A/S Earnings Call TranscriptNov 10, 2021€375 (-4.07%)Earnings
- Genmab A/S at Morgan Stanley Global Healthcare Conference (Virtual) TranscriptSep 09, 2021
- Q2 2021 Genmab A/S Earnings Call TranscriptAug 11, 2021€381.5 (-1.42%)Earnings
- Genmab A/S at Goldman Sachs Global Healthcare Conference (Virtual) TranscriptJun 09, 2021
- Q1 2021 Genmab A/S Earnings Call TranscriptMay 05, 2021€300.2 (+0.67%)Earnings
- Genmab A/S Annual Shareholders Meeting TranscriptApr 13, 2021
- Q4 2020 Genmab A/S Earnings Call TranscriptFeb 23, 2021€299.1 (-5.41%)Earnings
- Genmab A/S at JPMorgan Healthcare Conference (Virtual) TranscriptJan 13, 2021
- Genmab A/S Virtual 2020 ASH Data Review Meeting TranscriptDec 08, 2020
- Genmab A/S Virtual Capital Markets Day TranscriptNov 13, 2020
- Q3 2020 Genmab A/S Earnings Call TranscriptNov 04, 2020€318.1 (+8.90%)Earnings
- Genmab A/S at Morgan Stanley Global Healthcare Conference (Virtual) TranscriptSep 15, 2020
- Q2 2020 Genmab A/S Earnings Call TranscriptAug 12, 2020Earnings
- Genmab A/S at Goldman Sachs Global Healthcare Conference (Virtual) TranscriptJun 11, 2020
- Genmab A/S to Discuss Broad Oncology Collaboration with Abbvie Inc Call TranscriptJun 10, 2020
- Q1 2020 Genmab A/S Earnings Call TranscriptMay 06, 2020Earnings
- Genmab A/S Annual Shareholders Meeting TranscriptMar 26, 2020
- Genmab A/S at PR Newswire and BetterInvesting (NAIC) Deutsche Bank Depositary Receipts Virtual Investor Conference TranscriptMar 18, 2020
- Q4 2019 Genmab A/S Earnings Call TranscriptFeb 19, 2020Earnings
- Genmab A/S at JPMorgan Healthcare Conference TranscriptJan 15, 2020
- Genmab A/S 2019 R&D Update and ASH Data Review Meeting TranscriptDec 10, 2019
- Q3 2019 Genmab A/S Earnings Call TranscriptNov 06, 2019Earnings
- Q2 2019 Genmab A/S Earnings Call TranscriptAug 14, 2019Earnings
- Q1 2019 Genmab A/S Earnings Call TranscriptMay 08, 2019Earnings
- Q4 2018 Genmab A/S Earnings Call TranscriptFeb 20, 2019Earnings
Genmab A/S at Goldman Sachs Global Healthcare Conference Transcript
Jun 15, 2022 / 08:20PM GMT
Release Date Price:
€263.4
(-0.42%)
Nicholas Hallatt
Goldman Sachs Group, Inc., Research Division - Research Analyst
I'm excited to start our next session, where we're joined by Genmab. My name is Nick Hallatt. I work with the European Biopharma team out of London. I'm joined today by Anthony, the CFO; and Judith, the Chief Development Officer.
So perhaps, Anthony, if you'd like to kick off with an introduction to the company, a kind of overview of the technology platform that you developed.
Anthony Pagano;S;Executive VP;CFO
Genmab A
/-&
That would be super. Thanks, Nick. And it's great to be here today in person after so many years of doing this virtually. It's really super to be back here. So as you said, Nick, I'll just take a couple of minutes upfront, set a bit of context, and then I would really look forward to getting to your questions.
Nicholas Hallatt;Anthony Pagano
Goldman Sachs Group, Inc., Research Division - Research Analyst;Genmab A<
Perfect.
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent ![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust_rating.png)
4.6 out of 5
Trustpilot
![](https://static.gurufocus.com/trust.png)